SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?


To: scaram(o)uche who wrote (395)9/24/1999 5:00:00 PM
From: Biomaven  Read Replies (1) | Respond to of 52153
 
Pharma valuation is quite a different game, I feel. The major part of a pharma's value is in its present drugs, and the pipeline is a second order effect. For that matter, the same is true for a stock like AMGN.

I once promised Harold I would try to analyze BGEN by breaking it up into values for existing drugs vs. pipeline, but I never actually did it.

I wish I could follow the pharmas more closely, but I just don't have the time.

Peter